Echinocandins in the treatment of candidaemia and invasive candidiasis: Clinical and economic perspectives

International Journal of Antimicrobial Agents

Volumn 43, Issue 3, 2014, Pages 207-214

  Neoh, Chin Fen ^a,b   Slavin, Monica ^c   Chen, Sharon C A ^d   Stewart, Kay ^b   Kong, David C M ^b  

^a University of Technology Mara   (Malaysia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Candida infection; Costs; Echinocandins

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC ASPECT; HOSPITALIZATION COST; HUMAN; INCIDENCE; INFUSION RELATED REACTION; INVASIVE CANDIDIASIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

CANDIDA INFECTION; COSTS; ECHINOCANDINS;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; COST-BENEFIT ANALYSIS; ECHINOCANDINS; HEALTH CARE COSTS; HUMANS;

EID: 84896488395     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.08.010     Document Type: Short Survey

References (101)

1. K.A. Thursky, E.G. Playford, J.F. Seymour, T.C. Sorrell, D.H. Ellis, and S.D. Guy et al. Recommendations for the treatment of established fungal infections Intern Med J 38 2008 496 520
2. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
3. P. Eggimann, J. Garbino, and D. Pittet Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 2003 685 702
4. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317
5. A.I. Hidron, J.R. Edwards, J. Patel, T.C. Horan, D.M. Sievert, and D.A. Pollock et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect Control Hosp Epidemiol 29 2008 996 1011
6. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin et al. International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
7. D.L. Horn, J.A. Fishman, W.J. Steinbach, E.J. Anaissie, K.A. Marr, and A.J. Olyaei et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections Diagn Microbiol Infect Dis 59 2007 407 414
8. B. Almirante, D. Rodríguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, and M. Almela et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 2005 1829 1835
9. M.C. Arendrup, K. Fuursted, B. Gahrn-Hansen, I.M. Jensen, J.D. Knudsen, and B. Lundgren et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility J Clin Microbiol 43 2005 4434 4440
10. L.R. Asmundsdottir, H. Erlendsdottir, and M. Gottfredsson Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland J Clin Microbiol 40 2002 3489 3492
11. D.J. Diekema, S.A. Messer, A.B. Brueggemann, S.L. Coffman, G.V. Doern, and L.A. Herwaldt et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study J Clin Microbiol 40 2002 1298 1302
12. R.A. Hajjeh, A.N. Sofair, L.H. Harrison, G.M. Lyon, B.A. Arthington-Skaggs, and S.A. Mirza et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 2004 1519 1527
13. A.S. Kao, M.E. Brandt, W.R. Pruitt, L.A. Conn, B.A. Perkins, and D.S. Stephens et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance Clin Infect Dis 29 1999 1164 1170
14. K.B. Laupland, D.B. Gregson, D.L. Church, T. Ross, and S. Elsayed Invasive Candida species infections: a 5 year population-based assessment J Antimicrob Chemother 56 2005 532 537
15. F.C. Odds, M.F. Hanson, A.D. Davidson, M.D. Jacobsen, P. Wright, and J.A. Whyte et al. One year prospective survey of Candida bloodstream infections in Scotland J Med Microbiol 56 2007 1066 1075
16. E. Poikonen, O. Lyytikainen, V.J. Anttila, I. Koivula, J. Lumio, and P. Kotilainen et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007 BMC Infect Dis 10 2010 312
17. E. Poikonen, O. Lyytikainen, V.J. Anttila, and P. Ruutu Candidemia in Finland, 1995-1999 Emerg Infect Dis 9 2003 985 990
18. P. Sandven, L. Bevanger, A. Digranes, H.H. Haukland, T. Mannsaker, and P. Gaustad Candidemia in Norway (1991 to 2003): results from a nationwide study J Clin Microbiol 44 2006 1977 1981
19. S. Chen, M. Slavin, Q. Nguyen, D. Marriott, E.G. Playford, and D. Ellis et al. Active surveillance for candidemia, Australia Emerg Infect Dis 12 2006 1508 1516
20. M.A. Pfaller, and D.J. Diekema Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 20 2007 133 163
21. J. Morgan, M.I. Meltzer, B.D. Plikaytis, A.N. Sofair, S. Huie-White, and S. Wilcox et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance Infect Control Hosp Epidemiol 26 2005 540 547
22. A.M. Rentz, M.T. Halpern, and R. Bowden The impact of candidemia on length of hospital stay, outcome, and overall cost of illness Clin Infect Dis 27 1998 781 788
23. T.E. Zaoutis, J. Argon, J. Chu, J.A. Berlin, T.J. Walsh, and C. Feudtner The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis Clin Infect Dis 41 2005 1232 1239
24. I. Hassan, G. Powell, M. Sidhu, W.M. Hart, and D.W. Denning Excess mortality, length of stay and cost attributable to candidaemia J Infect 59 2009 360 365
25. W.E. Trick, S.K. Fridkin, J.R. Edwards, R.A. Hajjeh, and R.P. Gaynes Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999 Clin Infect Dis 35 2002 627 630
26. O. Gudlaugsson, S. Gillespie, K. Lee, J. Vande Berg, J. Hu, and S. Messer et al. Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
27. S.B. Wey, M. Mori, M.A. Pfaller, R.F. Woolson, and R.P. Wenzel Hospital-acquired candidemia. The attributable mortality and excess length of stay Arch Intern Med 148 1988 2642 2645
28. L. Puzniak, S. Teutsch, W. Powderly, and L. Polish Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 25 2004 628 633
29. J.A. Nieto-Rodriguez, S. Kusne, R. Mañez, W. Irish, P. Linden, and M. Magnone et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients Ann Surg 223 1996 70 76
30. J.J. Gagne, R.E. Breitbart, V. Maio, D.L. Horn, C. Hartmann, and R. Swanson et al. Cost associated with candidemia in a hospital setting P & T 31 2006 586 591 619
31. K.Z. Vardakas, A. Michalopoulos, K.G. Kiriakidou, E.P. Siampli, G. Samonis, and M.E. Falagas Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients Clin Microbiol Infect 15 2009 289 292
32. R.K. Pelz, P.A. Lipsett, S.M. Swoboda, M. Diener-West, N.R. Powe, and R.G. Brower et al. Candida infections: outcome and attributable ICU costs in critically ill patients J Intensive Care Med 15 2000 255 261
33. M.A. Pfaller, and D.J. Diekema Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus J Clin Microbiol 42 2004 4419 4431
34. M.E. Falagas, N. Roussos, and K.Z. Vardakas Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review Int J Infect Dis 14 2010 e954 e966
35. E.G. Playford, D. Marriott, Q. Nguyen, S. Chen, D. Ellis, and M. Slavin et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp Crit Care Med 36 2008 2034 2039
36. M.A. Slavin The epidemiology of candidaemia and mould infections in Australia J Antimicrob Chemother 49 Suppl. 1 2002 3 6
37. D.L. Horn, D. Neofytos, E.J. Anaissie, J.A. Fishman, W.J. Steinbach, and A.J. Olyaei et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry Clin Infect Dis 48 2009 1695 1703
38. R. Cisterna, G. Ezpeleta, and O. Telleria Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain J Clin Microbiol 48 2010 4200 4206
39. E.G. Playford, G.R. Nimmo, M. Tilse, and T.C. Sorrell Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008 J Hosp Infect 76 2010 46 51
40. N. Yapar, H. Pullukcu, V. Avkan-Oguz, S. Sayin-Kutlu, B. Ertugrul, and S. Sacar et al. Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study Med Mycol 49 2011 26 31
41. J.J. Gagne, and N.I. Goldfarb Candidemia in the in-patient setting: treatment options and economics Expert Opin Pharmacother 8 2007 1643 1650
42. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidaemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
43. H.M. Arnold, S.T. Micek, A.F. Shorr, M.D. Zilberberg, A.J. Labelle, and S. Kothari et al. Hospital resource utilization and costs of inappropriate treatment of candidemia Pharmacotherapy 30 2010 361 368
44. M. Morrell, V.J. Fraser, and M.H. Kollef Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 2005 3640 3645
45. Y. Taur, N. Cohen, S. Dubnow, A. Paskovaty, and S.K. Seo Effect of antifungal therapy timing on mortality in cancer patients with candidemia Antimicrob Agents Chemother 54 2010 184 190
46. M.D. Zilberberg, M.H. Kollef, H. Arnold, A. Labelle, S.T. Micek, and S. Kothari et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study BMC Infect Dis 10 2010 150
47. K.W. Garey, R.S. Turpin, D.T. Bearden, M.P. Pai, and K.J. Suda Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study Int J Antimicrob Agents 29 2007 557 562
48. O.A. Cornely, M. Bassetti, T. Calandra, J. Garbino, B.J. Kullberg, and O. Lortholary et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients Clin Microbiol Infect 18 Suppl. 7 2012 19 37
49. M. Ruhnke, V. Rickerts, O.A. Cornely, D. Buchheidt, A. Glockner, and W. Heinz et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy Mycoses 54 2011 279 310
50. E.K. Spanakis, G. Aperis, and E. Mylonakis New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage Clin Infect Dis 43 2006 1060 1068
51. E.J. Anaissie, R.O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, and L.O. Gentry et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature Clin Infect Dis 23 1996 964 972
52. P. Phillips, S. Shafran, G. Garber, C. Rotstein, F. Smaill, and I. Fong et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group Eur J Clin Microbiol Infect Dis 16 1997 337 345
53. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. van der Horst, and J.E. Edwards et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute N Engl J Med 331 1994 1325 1330
54. L. Ostrosky-Zeichner, and P.G. Pappas Invasive candidiasis in the intensive care unit Crit Care Med 34 2006 857 863
55. L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, R.J. Hamill, R.A. Larsen, and H.W. Horowitz et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
56. M.A. Pfaller, D.J. Diekema, and D.J. Sheehan Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing Clin Microbiol Rev 19 2006 435 447
57. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
58. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana et al. Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
59. E-R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadharao et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
60. F. Queiroz-Telles, E. Berezin, G. Leverger, A. Freire, A. van der Vyver, and T. Chotpitayasunondh et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial Pediatr Infect Dis J 27 2008 820 826
61. P.G. Pappas, C.M.F. Rotstein, R.F. Betts, M. Nucci, D. Talwar, and J.J. De Waele et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 2007 883 893
62. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar et al. Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
63. R.F. Betts, M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, and R.J. Bedimo et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 2009 1676 1684
64. D.H. Kett, A.F. Shorr, A.C. Reboli, A.C. Reisman, P. Biswas, and H.T. Schlamm Anidulafungin compared with fluconazole therapy in critically ill patients Crit Care 14 Suppl. 1 2010 P72
65. A. Gafter-Gvili, L. Vidal, E. Goldberg, L. Leibovici, and M. Paul Treatment of invasive candidal infections: systematic review and meta-analysis Mayo Clin Proc 83 2008 1011 1021
66. Y. Golan, D. Harrison, and K. Fahrbach An echinocandin vs. A comparator antifungal in Candida bloodstream infections: a meta-analysis Abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 April 2010, Vienna, Austria 2010 European Society of Clinical Microbiology and Infectious Diseases Taufkirchen, Germany [abstract O410]
67. D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, and J.H. Rex et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin Infect Dis 54 2012 1110 1122
68. D.B. Petitti Meta-analysis, decision analysis, and cost-effectiveness analysis 2000 Oxford University Press New York, NY
69. M.F. Drummond, M.J. Sculpher, G.W. Torrance, B.J. O'Brien, and G.L. Stoddart Methods for the economic evaluation of health care programmes 2000 Oxford University Press New York, NY
70. R. Arenas-Guzman, A. Tosti, R. Hay, and E. Haneke National Institute for Clinical Excellence. Pharmacoeconomics - an aid to better decision-making J Eur Acad Dermatol Venereol 19 Suppl. 1 2005 34 39
71. S.R. Earnshaw, C.N. Graham, and S.M. Gasper Cost-effectiveness of anidulafungin in confirmed candidemia and other invasive candidiasis Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 17-20 September 2007, Chicago, IL 2007 American Society of Microbiology Washington, DC [abstract O1867]
72. A. Reboli, C. Rotstein, D. Kett, D. Shorr, R. Chambers, and M. Hux Economic evaluation of anidulafungin versus intravenous fluconazole in the treatment of hospital inpatients diagnosed with candidaemia and other forms of invasive candidiasis Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 16-19 May 2009, Helsinki, Finland 2009 European Society of Clinical Microbiology and Infectious Diseases Taufkirchen, Germany [abstract P1746]
73. S. Grau, M. García, B. Martí, and N. Mir Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive candidiasis in Spain Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 16-19 May 2009, Helsinki, Finland 2009 European Society of Clinical Microbiology and Infectious Diseases Taufkirchen, Germany [abstract P1745]
74. G. Park, M. Sidhu, A.K. Van Engen, and O. Schoeman Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in the United Kingdom Abstracts of the 13th annual international meeting of the International Society for Pharmacoeconomics and Outcome Research 3-7 May 2008, Toronto, Canada 2008 International Society for Pharmacoeconomics and Outcome Research Lawrenceville, NJ [abstract PIN27]
75. P. Viale, M. Sidhu, A. van Engen, and O. Schoeman Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Italy Abstracts of the 11th annual European Congress of the International Society for Pharmacoeconomics and Outcome Research 8-11 November 2008, Athens, Greece 2008 International Society for Pharmacoeconomics and Outcome Research Lawrenceville, NJ [abstract PIN13]
76. M. García, B. Martí, and B. Ferro Budget impact analysis of three candins in the treatment of invasive candidiasis in adult non-neutropenic patients in Spain Abstracts of the 12th annual European Congress of the International Society for Pharmacoeconomics and Outcome Research 24-27 October 2009, Paris, France 2009 International Society for Pharmacoeconomics and Outcome Research Lawrenceville, NJ [abstract PIN12]
77. G. Dranitsaris, P. Phillips, C. Rotstein, A. Puodziunas, S. Shafran, and G. Garber et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients Pharmacoeconomics 13 1998 509 518
78. O.A. Cornely, M. Sidhu, I. Odeyemi, A.K. van Engen, J.M. van der Waal, and O. Schoeman Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany Curr Med Res Opin 24 2008 1743 1753
79. C. Rotstein, L. Cragin, M. Laverdiere, G. Garber, E.J. Bow, and A. Scalera et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults Can J Infect Dis Med Microbiol 19 2008 219 226
80. M.K. Sidhu, A.K. van Engen, J. Kleintjens, O. Schoeman, and M. Palazzo Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK Curr Med Res Opin 25 2009 2049 2059
81. J.R. Wingard, C.A. Wood, E. Sullivan, M.L. Berger, W.C. Gerth, and E.C. Mansley Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis Clin Ther 27 2005 960 969
82. A.C. Reboli, C. Rotstein, D.H. Kett, M. Maschio, S. Cartier, and R. Chambers et al. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients Pharmacoeconomics 29 2011 705 717
83. C.F. Neoh, D. Liew, M. Slavin, D. Marriott, S. Chen, and O. Morrissey et al. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis (IC) J Antimicrob Chemother 66 2011 1906 1915
84. J. Nixon, B. Stoykova, J. Glanville, J. Christie, M. Drummond, and J. Kleijnen The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology Int J Technol Assess Health Care 16 2000 731 742
85. S. Jain, and N.K. Arora Randomised controlled trial and economic evaluation Indian J Pediatr 67 2000 363 368
86. M.J. Buxton, M.F. Drummond, B.A. Van Hout, R.L. Prince, T.A. Sheldon, and T. Szucs et al. Modelling in economic evaluation: an unavoidable fact of life Health Econ 6 1997 217 227
87. M.J. Sculpher, K. Claxton, M. Drummond, and C. McCabe Whither trial-based economic evaluation for health care decision making? Health Econ 15 2006 677 687
88. S. Petrou, and A. Gray Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting BMJ 342 2011 d1766
89. B. George, A. Harris, and A. Mitchell Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996) Pharmacoeconomics 19 2001 1103 1109
90. C.F. Neoh, D. Liew, M.A. Slavin, D. Marriott, S.C. Chen, and O. Morrissey et al. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC) Mycoses 56 2013 532 542
91. C.F. Neoh, D. Liew, M.A. Slavin, D. Marriott, S.C. Chen, and O. Morrissey et al. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis Intern Med J 43 2013 668 677
92. K. Marfo, and Y. Guo Pharmacoeconomic analysis of micafungin (Mycamine) 100 mg and 150 mg daily in the treatment of candidemia P & T 34 2009 196 199
93. A. Briggs Transportability of comparative effectiveness and cost-effectiveness between countries Value Health 13 Suppl. 1 2010 S22 S25
94. B.J. O'Brien A tale of two (or more) cities: geographic transferability of pharmacoeconomic data Am J Manag Care 3 Suppl. 5 1997 S33 S39
95. D. Al-Badriyeh, D. Liew, K. Stewart, and D.C. Kong Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia J Antimicrob Chemother 63 2009 197 208
96. C.D. Collins, E.R. Stuntebeck, D.D. DePestel, and J.G. Stevenson Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia Clin Drug Investig 27 2007 233 241
97. J.W. Hay Evaluation and review of pharmacoeconomic models Expert Opin Pharmacother 5 2004 1867 1880
98. S. Dixon, E. McKeen, M. Tabberer, and S. Paisley Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature Pharmacoeconomics 22 2004 421 433
99. M.D. Johnson, M. Kleinberg, L. Danziger, and L. Ostrosky-Zeichner Pharmacoeconomics of antifungal pharmacotherapy: challenges and future directions Expert Opin Pharmacother 6 2005 2617 2632
100. M. Gold, J. Siegel, L. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York, NY
101. G.N. Forrest, K. Mankes, M.A. Jabra-Rizk, E. Weekes, J.K. Johnson, and D.P. Lincalis et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs J Clin Microbiol 44 2006 3381 3383